id	sid	tid	token	lemma	pos
dpc-4642	1	1	dermatology	dermatology	NOUN
dpc-4642	1	2	:	:	PUNCT
dpc-4642	1	3	practical	practical	ADJ
dpc-4642	1	4	and	and	CCONJ
dpc-4642	1	5	conceptual	conceptual	ADJ
dpc-4642	1	6	image	image	NOUN
dpc-4642	1	7	letter	letter	NOUN
dpc-4642	2	1	|	|	ADV
dpc-4642	2	2	dermatol	dermatol	ADJ
dpc-4642	2	3	pract	pract	NOUN
dpc-4642	2	4	concept	concept	NOUN
dpc-4642	2	5	.	.	PUNCT
dpc-4642	3	1	2025;15(1	2025;15(1	NUM
dpc-4642	3	2	):	):	PUNCT
dpc-4642	3	3	4642	4642	NUM
dpc-4642	3	4	1	1	NUM
dpc-4642	3	5	non	non	ADJ
dpc-4642	3	6	-	-	ADJ
dpc-4642	3	7	melanoma	melanoma	ADJ
dpc-4642	3	8	skin	skin	NOUN
dpc-4642	3	9	cancer	cancer	NOUN
dpc-4642	3	10	aggravation	aggravation	NOUN
dpc-4642	3	11	in	in	ADP
dpc-4642	3	12	polycythemia	polycythemia	NOUN
dpc-4642	3	13	vera	vera	NOUN
dpc-4642	3	14	:	:	PUNCT
dpc-4642	3	15	triggered	trigger	VERB
dpc-4642	3	16	by	by	ADP
dpc-4642	3	17	ruxolitinib	ruxolitinib	NOUN
dpc-4642	3	18	and	and	CCONJ
dpc-4642	3	19	silenced	silence	VERB
dpc-4642	3	20	with	with	ADP
dpc-4642	3	21	an	an	DET
dpc-4642	3	22	ifn	ifn	NOUN
dpc-4642	3	23	/	/	SYM
dpc-4642	3	24	cemiplimab	cemiplimab	NOUN
dpc-4642	3	25	efterpi	efterpi	NOUN
dpc-4642	3	26	zafiriou1	zafiriou1	PROPN
dpc-4642	3	27	,	,	PUNCT
dpc-4642	3	28	emmanouil	emmanouil	PROPN
dpc-4642	3	29	karampinis1	karampinis1	NOUN
dpc-4642	3	30	,	,	PUNCT
dpc-4642	3	31	vasileios	vasileio	NOUN
dpc-4642	3	32	papadopoulos3	papadopoulos3	NOUN
dpc-4642	3	33	,	,	PUNCT
dpc-4642	3	34	georgia	georgia	PROPN
dpc-4642	3	35	stefani2	stefani2	PROPN
dpc-4642	3	36	,	,	PUNCT
dpc-4642	3	37	athanasios	athanasios	PROPN
dpc-4642	3	38	kotsakis3	kotsakis3	PROPN
dpc-4642	3	39	,	,	PUNCT
dpc-4642	3	40	george	george	PROPN
dpc-4642	3	41	vassilopoulos2	vassilopoulos2	PROPN
dpc-4642	3	42	1	1	NUM
dpc-4642	3	43	department	department	NOUN
dpc-4642	3	44	of	of	ADP
dpc-4642	3	45	dermatology	dermatology	NOUN
dpc-4642	3	46	,	,	PUNCT
dpc-4642	3	47	faculty	faculty	NOUN
dpc-4642	3	48	of	of	ADP
dpc-4642	3	49	medicine	medicine	NOUN
dpc-4642	3	50	,	,	PUNCT
dpc-4642	3	51	school	school	NOUN
dpc-4642	3	52	of	of	ADP
dpc-4642	3	53	health	health	NOUN
dpc-4642	3	54	sciences	sciences	PROPN
dpc-4642	3	55	,	,	PUNCT
dpc-4642	3	56	university	university	NOUN
dpc-4642	3	57	general	general	ADJ
dpc-4642	3	58	hospital	hospital	NOUN
dpc-4642	3	59	of	of	ADP
dpc-4642	3	60	larissa	larissa	PROPN
dpc-4642	3	61	,	,	PUNCT
dpc-4642	3	62	university	university	PROPN
dpc-4642	3	63	of	of	ADP
dpc-4642	3	64	thessaly	thessaly	PROPN
dpc-4642	3	65	,	,	PUNCT
dpc-4642	3	66	larissa	larissa	PROPN
dpc-4642	3	67	,	,	PUNCT
dpc-4642	3	68	greece	greece	PROPN
dpc-4642	3	69	2	2	NUM
dpc-4642	3	70	department	department	NOUN
dpc-4642	3	71	of	of	ADP
dpc-4642	3	72	hematology	hematology	PROPN
dpc-4642	3	73	,	,	PUNCT
dpc-4642	3	74	uhl	uhl	PROPN
dpc-4642	3	75	,	,	PUNCT
dpc-4642	3	76	university	university	PROPN
dpc-4642	3	77	of	of	ADP
dpc-4642	3	78	thessaly	thessaly	PROPN
dpc-4642	3	79	medical	medical	PROPN
dpc-4642	3	80	school	school	PROPN
dpc-4642	3	81	,	,	PUNCT
dpc-4642	3	82	larissa	larissa	PROPN
dpc-4642	3	83	,	,	PUNCT
dpc-4642	3	84	greece	greece	PROPN
dpc-4642	3	85	3	3	NUM
dpc-4642	3	86	department	department	PROPN
dpc-4642	3	87	of	of	ADP
dpc-4642	3	88	oncology	oncology	NOUN
dpc-4642	3	89	,	,	PUNCT
dpc-4642	3	90	university	university	NOUN
dpc-4642	3	91	general	general	ADJ
dpc-4642	3	92	hospital	hospital	NOUN
dpc-4642	3	93	of	of	ADP
dpc-4642	3	94	larissa	larissa	PROPN
dpc-4642	3	95	,	,	PUNCT
dpc-4642	3	96	larissa	larissa	PROPN
dpc-4642	3	97	,	,	PUNCT
dpc-4642	3	98	greece	greece	PROPN
dpc-4642	3	99	citation	citation	PROPN
dpc-4642	3	100	:	:	PUNCT
dpc-4642	3	101	zafiriou	zafiriou	NOUN
dpc-4642	3	102	e	e	NOUN
dpc-4642	3	103	,	,	PUNCT
dpc-4642	3	104	karampinis	karampinis	PROPN
dpc-4642	3	105	e	e	PROPN
dpc-4642	3	106	,	,	PUNCT
dpc-4642	3	107	papadopoulos	papadopoulos	PROPN
dpc-4642	3	108	v	v	PROPN
dpc-4642	3	109	,	,	PUNCT
dpc-4642	3	110	stefani	stefani	PROPN
dpc-4642	3	111	g	g	PROPN
dpc-4642	3	112	,	,	PUNCT
dpc-4642	3	113	kotsakis	kotsakis	PROPN
dpc-4642	3	114	a	a	PROPN
dpc-4642	3	115	,	,	PUNCT
dpc-4642	3	116	vassilopoulos	vassilopoulos	PROPN
dpc-4642	3	117	g.	g.	PROPN
dpc-4642	3	118	non	non	ADJ
dpc-4642	3	119	-	-	ADJ
dpc-4642	3	120	melanoma	melanoma	ADJ
dpc-4642	3	121	skin	skin	NOUN
dpc-4642	3	122	cancer	cancer	NOUN
dpc-4642	3	123	aggravation	aggravation	NOUN
dpc-4642	3	124	in	in	ADP
dpc-4642	3	125	polycythemia	polycythemia	NOUN
dpc-4642	3	126	vera	vera	NOUN
dpc-4642	3	127	:	:	PUNCT
dpc-4642	3	128	triggered	trigger	VERB
dpc-4642	3	129	by	by	ADP
dpc-4642	3	130	ruxolitinib	ruxolitinib	NOUN
dpc-4642	3	131	and	and	CCONJ
dpc-4642	3	132	silenced	silence	VERB
dpc-4642	3	133	with	with	ADP
dpc-4642	3	134	an	an	DET
dpc-4642	3	135	ifn	ifn	NOUN
dpc-4642	3	136	/	/	SYM
dpc-4642	3	137	cemiplimab	cemiplimab	NOUN
dpc-4642	3	138	.	.	PUNCT
dpc-4642	4	1	dermatol	dermatol	NOUN
dpc-4642	4	2	pract	pract	PROPN
dpc-4642	4	3	concept	concept	NOUN
dpc-4642	4	4	.	.	PUNCT
dpc-4642	5	1	2025;15(1	2025;15(1	NUM
dpc-4642	5	2	):	):	PUNCT
dpc-4642	5	3	4642	4642	NUM
dpc-4642	5	4	.	.	PUNCT
dpc-4642	6	1	doi	doi	NOUN
dpc-4642	6	2	:	:	PUNCT
dpc-4642	6	3	https://doi.org/10.5826/dpc.1501a4642	https://doi.org/10.5826/dpc.1501a4642	PROPN
dpc-4642	6	4	accepted	accept	VERB
dpc-4642	6	5	:	:	PUNCT
dpc-4642	6	6	october	october	PROPN
dpc-4642	6	7	20	20	NUM
dpc-4642	6	8	,	,	PUNCT
dpc-4642	6	9	2024	2024	NUM
dpc-4642	6	10	;	;	PUNCT
dpc-4642	6	11	published	publish	VERB
dpc-4642	6	12	:	:	PUNCT
dpc-4642	7	1	january	january	PROPN
dpc-4642	7	2	2025	2025	NUM
dpc-4642	7	3	copyright	copyright	NOUN
dpc-4642	7	4	:	:	PUNCT
dpc-4642	7	5	©	©	PROPN
dpc-4642	7	6	2024	2024	NUM
dpc-4642	7	7	zafiriou	zafiriou	NOUN
dpc-4642	7	8	et	et	NOUN
dpc-4642	7	9	al	al	PROPN
dpc-4642	7	10	.	.	PUNCT
dpc-4642	8	1	this	this	PRON
dpc-4642	8	2	is	be	AUX
dpc-4642	8	3	an	an	DET
dpc-4642	8	4	open	open	ADJ
dpc-4642	8	5	-	-	PUNCT
dpc-4642	8	6	access	access	NOUN
dpc-4642	8	7	article	article	NOUN
dpc-4642	8	8	distributed	distribute	VERB
dpc-4642	8	9	under	under	ADP
dpc-4642	8	10	the	the	DET
dpc-4642	8	11	terms	term	NOUN
dpc-4642	8	12	of	of	ADP
dpc-4642	8	13	the	the	DET
dpc-4642	8	14	creative	creative	ADJ
dpc-4642	8	15	commons	common	NOUN
dpc-4642	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4642	8	17	license	license	NOUN
dpc-4642	8	18	(	(	PUNCT
dpc-4642	8	19	by	by	ADP
dpc-4642	8	20	-	-	PUNCT
dpc-4642	8	21	nc-4.0	nc-4.0	NOUN
dpc-4642	8	22	)	)	PUNCT
dpc-4642	8	23	,	,	PUNCT
dpc-4642	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4642	8	25	,	,	PUNCT
dpc-4642	8	26	which	which	PRON
dpc-4642	8	27	permits	permit	VERB
dpc-4642	8	28	unrestricted	unrestricted	ADJ
dpc-4642	8	29	noncommercial	noncommercial	ADJ
dpc-4642	8	30	use	use	NOUN
dpc-4642	8	31	,	,	PUNCT
dpc-4642	8	32	distribution	distribution	NOUN
dpc-4642	8	33	,	,	PUNCT
dpc-4642	8	34	and	and	CCONJ
dpc-4642	8	35	reproduction	reproduction	NOUN
dpc-4642	8	36	in	in	ADP
dpc-4642	8	37	any	any	DET
dpc-4642	8	38	medium	medium	NOUN
dpc-4642	8	39	,	,	PUNCT
dpc-4642	8	40	provided	provide	VERB
dpc-4642	8	41	the	the	DET
dpc-4642	8	42	original	original	ADJ
dpc-4642	8	43	authors	author	NOUN
dpc-4642	8	44	and	and	CCONJ
dpc-4642	8	45	source	source	NOUN
dpc-4642	8	46	are	be	AUX
dpc-4642	8	47	credited	credit	VERB
dpc-4642	8	48	.	.	PUNCT
dpc-4642	9	1	funding	funding	NOUN
dpc-4642	9	2	:	:	PUNCT
dpc-4642	9	3	none	none	NOUN
dpc-4642	9	4	.	.	PUNCT
dpc-4642	10	1	competing	compete	VERB
dpc-4642	10	2	interests	interest	NOUN
dpc-4642	10	3	:	:	PUNCT
dpc-4642	10	4	none	none	NOUN
dpc-4642	10	5	.	.	PUNCT
dpc-4642	11	1	authorship	authorship	NOUN
dpc-4642	11	2	:	:	PUNCT
dpc-4642	11	3	all	all	DET
dpc-4642	11	4	authors	author	NOUN
dpc-4642	11	5	have	have	AUX
dpc-4642	11	6	contributed	contribute	VERB
dpc-4642	11	7	significantly	significantly	ADV
dpc-4642	11	8	to	to	ADP
dpc-4642	11	9	this	this	DET
dpc-4642	11	10	publication	publication	NOUN
dpc-4642	11	11	.	.	PUNCT
dpc-4642	12	1	corresponding	correspond	VERB
dpc-4642	12	2	author	author	NOUN
dpc-4642	12	3	:	:	PUNCT
dpc-4642	12	4	efterpi	efterpi	ADJ
dpc-4642	12	5	zafiriou	zafiriou	NOUN
dpc-4642	12	6	,	,	PUNCT
dpc-4642	12	7	department	department	NOUN
dpc-4642	12	8	of	of	ADP
dpc-4642	12	9	dermatology	dermatology	NOUN
dpc-4642	12	10	,	,	PUNCT
dpc-4642	12	11	faculty	faculty	NOUN
dpc-4642	12	12	of	of	ADP
dpc-4642	12	13	medicine	medicine	NOUN
dpc-4642	12	14	,	,	PUNCT
dpc-4642	12	15	school	school	NOUN
dpc-4642	12	16	of	of	ADP
dpc-4642	12	17	health	health	NOUN
dpc-4642	12	18	sciences	sciences	PROPN
dpc-4642	12	19	,	,	PUNCT
dpc-4642	12	20	university	university	NOUN
dpc-4642	12	21	general	general	ADJ
dpc-4642	12	22	hospital	hospital	NOUN
dpc-4642	12	23	of	of	ADP
dpc-4642	12	24	larissa	larissa	PROPN
dpc-4642	12	25	,	,	PUNCT
dpc-4642	12	26	university	university	PROPN
dpc-4642	12	27	of	of	ADP
dpc-4642	12	28	thessaly	thessaly	PROPN
dpc-4642	12	29	,	,	PUNCT
dpc-4642	12	30	41110	41110	NUM
dpc-4642	12	31	larissa	larissa	PROPN
dpc-4642	12	32	,	,	PUNCT
dpc-4642	12	33	greece	greece	PROPN
dpc-4642	12	34	email	email	NOUN
dpc-4642	12	35	:	:	PUNCT
dpc-4642	12	36	zafevi@o365.uth.gr	zafevi@o365.uth.gr	NOUN
dpc-4642	12	37	case	case	NOUN
dpc-4642	12	38	presentation	presentation	NOUN
dpc-4642	12	39	a	a	DET
dpc-4642	12	40	patient	patient	NOUN
dpc-4642	12	41	with	with	ADP
dpc-4642	12	42	jak2	jak2	NOUN
dpc-4642	12	43	+	+	CCONJ
dpc-4642	12	44	polycythemia	polycythemia	NOUN
dpc-4642	12	45	vera	vera	NOUN
dpc-4642	12	46	(	(	PUNCT
dpc-4642	12	47	pv	pv	NOUN
dpc-4642	12	48	)	)	PUNCT
dpc-4642	12	49	was	be	AUX
dpc-4642	12	50	started	start	VERB
dpc-4642	12	51	on	on	ADP
dpc-4642	12	52	ruxolitinib	ruxolitinib	NOUN
dpc-4642	12	53	after	after	ADP
dpc-4642	12	54	inadequate	inadequate	ADJ
dpc-4642	12	55	disease	disease	NOUN
dpc-4642	12	56	control	control	NOUN
dpc-4642	12	57	with	with	ADP
dpc-4642	12	58	initial	initial	ADJ
dpc-4642	12	59	therapy	therapy	NOUN
dpc-4642	12	60	,	,	PUNCT
dpc-4642	12	61	which	which	PRON
dpc-4642	12	62	was	be	AUX
dpc-4642	12	63	later	later	ADV
dpc-4642	12	64	increased	increase	VERB
dpc-4642	12	65	to	to	ADP
dpc-4642	12	66	20	20	NUM
dpc-4642	12	67	mg	mg	NOUN
dpc-4642	12	68	twice	twice	ADV
dpc-4642	12	69	daily	daily	ADV
dpc-4642	12	70	.	.	PUNCT
dpc-4642	13	1	two	two	NUM
dpc-4642	13	2	months	month	NOUN
dpc-4642	13	3	later	later	ADV
dpc-4642	13	4	,	,	PUNCT
dpc-4642	13	5	the	the	DET
dpc-4642	13	6	patient	patient	NOUN
dpc-4642	13	7	developed	develop	VERB
dpc-4642	13	8	a	a	DET
dpc-4642	13	9	large	large	ADJ
dpc-4642	13	10	ulcerative	ulcerative	ADJ
dpc-4642	13	11	nasal	nasal	ADJ
dpc-4642	13	12	lesion	lesion	NOUN
dpc-4642	13	13	,	,	PUNCT
dpc-4642	13	14	diagnosed	diagnose	VERB
dpc-4642	13	15	as	as	ADP
dpc-4642	13	16	squamous	squamous	ADJ
dpc-4642	13	17	cell	cell	NOUN
dpc-4642	13	18	carcinoma	carcinoma	NOUN
dpc-4642	13	19	(	(	PUNCT
dpc-4642	13	20	scc	scc	NOUN
dpc-4642	13	21	)	)	PUNCT
dpc-4642	13	22	(	(	PUNCT
dpc-4642	13	23	figure	figure	NOUN
dpc-4642	13	24	 	 	SPACE
dpc-4642	13	25	1	1	NUM
dpc-4642	13	26	)	)	PUNCT
dpc-4642	13	27	.	.	PUNCT
dpc-4642	14	1	this	this	DET
dpc-4642	14	2	lesion	lesion	NOUN
dpc-4642	14	3	was	be	AUX
dpc-4642	14	4	a	a	DET
dpc-4642	14	5	recurrence	recurrence	NOUN
dpc-4642	14	6	of	of	ADP
dpc-4642	14	7	a	a	DET
dpc-4642	14	8	nasal	nasal	ADJ
dpc-4642	14	9	epithelioma	epithelioma	NOUN
dpc-4642	14	10	that	that	PRON
dpc-4642	14	11	had	have	AUX
dpc-4642	14	12	been	be	AUX
dpc-4642	14	13	surgically	surgically	ADV
dpc-4642	14	14	removed	remove	VERB
dpc-4642	14	15	30	30	NUM
dpc-4642	14	16	months	month	NOUN
dpc-4642	14	17	prior	prior	ADV
dpc-4642	14	18	.	.	PUNCT
dpc-4642	15	1	ruxolitinib	ruxolitinib	NOUN
dpc-4642	15	2	was	be	AUX
dpc-4642	15	3	discontinued	discontinue	VERB
dpc-4642	15	4	,	,	PUNCT
dpc-4642	15	5	and	and	CCONJ
dpc-4642	15	6	ropeginterferon	ropeginterferon	NOUN
dpc-4642	15	7	alfa-2b	alfa-2b	CCONJ
dpc-4642	15	8	was	be	AUX
dpc-4642	15	9	introduced	introduce	VERB
dpc-4642	15	10	.	.	PUNCT
dpc-4642	16	1	the	the	DET
dpc-4642	16	2	patient	patient	NOUN
dpc-4642	16	3	achieved	achieve	VERB
dpc-4642	16	4	full	full	ADJ
dpc-4642	16	5	hematological	hematological	ADJ
dpc-4642	16	6	and	and	CCONJ
dpc-4642	16	7	clinical	clinical	ADJ
dpc-4642	16	8	response	response	NOUN
dpc-4642	16	9	with	with	ADP
dpc-4642	16	10	350	350	NUM
dpc-4642	16	11	mg	mg	PROPN
dpc-4642	16	12	ropeginterferon	ropeginterferon	NOUN
dpc-4642	16	13	alfa-2b	alfa-2b	CCONJ
dpc-4642	16	14	every	every	DET
dpc-4642	16	15	15	15	NUM
dpc-4642	16	16	days	day	NOUN
dpc-4642	16	17	.	.	PUNCT
dpc-4642	17	1	cemiplimab	cemiplimab	NOUN
dpc-4642	17	2	was	be	AUX
dpc-4642	17	3	then	then	ADV
dpc-4642	17	4	added	add	VERB
dpc-4642	17	5	for	for	ADP
dpc-4642	17	6	the	the	DET
dpc-4642	17	7	recurrent	recurrent	PROPN
dpc-4642	17	8	scc	scc	NOUN
dpc-4642	17	9	,	,	PUNCT
dpc-4642	17	10	resulting	result	VERB
dpc-4642	17	11	in	in	ADP
dpc-4642	17	12	satisfactory	satisfactory	ADJ
dpc-4642	17	13	lesion	lesion	NOUN
dpc-4642	17	14	regression	regression	NOUN
dpc-4642	17	15	(	(	PUNCT
dpc-4642	17	16	figure	figure	NOUN
dpc-4642	17	17	1	1	NUM
dpc-4642	17	18	)	)	PUNCT
dpc-4642	17	19	without	without	ADP
dpc-4642	17	20	adverse	adverse	ADJ
dpc-4642	17	21	effects	effect	NOUN
dpc-4642	17	22	probably	probably	ADV
dpc-4642	17	23	due	due	ADJ
dpc-4642	17	24	to	to	ADP
dpc-4642	17	25	the	the	DET
dpc-4642	17	26	combined	combine	VERB
dpc-4642	17	27	benefits	benefit	NOUN
dpc-4642	17	28	of	of	ADP
dpc-4642	17	29	interferon	interferon	NOUN
dpc-4642	17	30	and	and	CCONJ
dpc-4642	17	31	pd-1	pd-1	ADV
dpc-4642	17	32	inhibition	inhibition	NOUN
dpc-4642	17	33	.	.	PUNCT
dpc-4642	18	1	teaching	teaching	NOUN
dpc-4642	18	2	point	point	NOUN
dpc-4642	18	3	ruxolitinib	ruxolitinib	NOUN
dpc-4642	18	4	,	,	PUNCT
dpc-4642	18	5	a	a	DET
dpc-4642	18	6	jak	jak	PROPN
dpc-4642	18	7	-	-	PUNCT
dpc-4642	18	8	stat	stat	PROPN
dpc-4642	18	9	pathway	pathway	NOUN
dpc-4642	18	10	inhibitor	inhibitor	NOUN
dpc-4642	18	11	,	,	PUNCT
dpc-4642	18	12	has	have	AUX
dpc-4642	18	13	been	be	AUX
dpc-4642	18	14	approved	approve	VERB
dpc-4642	18	15	for	for	ADP
dpc-4642	18	16	treating	treat	VERB
dpc-4642	18	17	pv	pv	ADP
dpc-4642	18	18	in	in	ADP
dpc-4642	18	19	patients	patient	NOUN
dpc-4642	18	20	who	who	PRON
dpc-4642	18	21	are	be	AUX
dpc-4642	18	22	intolerant	intolerant	ADJ
dpc-4642	18	23	or	or	CCONJ
dpc-4642	18	24	resistant	resistant	ADJ
dpc-4642	18	25	to	to	ADP
dpc-4642	18	26	hydroxyurea	hydroxyurea	PROPN
dpc-4642	18	27	.	.	PUNCT
dpc-4642	19	1	it	it	PRON
dpc-4642	19	2	effectively	effectively	ADV
dpc-4642	19	3	alleviates	alleviate	VERB
dpc-4642	19	4	systemic	systemic	ADJ
dpc-4642	19	5	symptoms	symptom	NOUN
dpc-4642	19	6	,	,	PUNCT
dpc-4642	19	7	controls	control	VERB
dpc-4642	19	8	hematocrit	hematocrit	ADJ
dpc-4642	19	9	counts	count	NOUN
dpc-4642	19	10	,	,	PUNCT
dpc-4642	19	11	and	and	CCONJ
dpc-4642	19	12	reduces	reduce	VERB
dpc-4642	19	13	spleen	spleen	NOUN
dpc-4642	19	14	volume	volume	NOUN
dpc-4642	19	15	.	.	PUNCT
dpc-4642	20	1	however	however	ADV
dpc-4642	20	2	,	,	PUNCT
dpc-4642	20	3	reports	report	NOUN
dpc-4642	20	4	highlight	highlight	VERB
dpc-4642	20	5	a	a	DET
dpc-4642	20	6	high	high	ADJ
dpc-4642	20	7	incidence	incidence	NOUN
dpc-4642	20	8	of	of	ADP
dpc-4642	20	9	aggressive	aggressive	ADJ
dpc-4642	20	10	non	non	ADJ
dpc-4642	20	11	-	-	ADJ
dpc-4642	20	12	melanoma	melanoma	ADJ
dpc-4642	20	13	skin	skin	NOUN
dpc-4642	20	14	cancers	cancer	NOUN
dpc-4642	20	15	among	among	ADP
dpc-4642	20	16	ruxolitinib	ruxolitinib	NOUN
dpc-4642	20	17	-	-	PUNCT
dpc-4642	20	18	treated	treat	VERB
dpc-4642	20	19	2	2	NUM
dpc-4642	20	20	image	image	NOUN
dpc-4642	20	21	letter	letter	NOUN
dpc-4642	20	22	|	|	ADV
dpc-4642	20	23	dermatol	dermatol	ADJ
dpc-4642	20	24	pract	pract	NOUN
dpc-4642	20	25	concept	concept	NOUN
dpc-4642	20	26	.	.	PUNCT
dpc-4642	21	1	2025;15(1	2025;15(1	NUM
dpc-4642	21	2	):	):	PUNCT
dpc-4642	21	3	4642	4642	NUM
dpc-4642	21	4	patients	patient	NOUN
dpc-4642	21	5	,	,	PUNCT
dpc-4642	21	6	with	with	ADP
dpc-4642	21	7	poor	poor	ADJ
dpc-4642	21	8	or	or	CCONJ
dpc-4642	21	9	moderate	moderate	ADJ
dpc-4642	21	10	differentiation	differentiation	NOUN
dpc-4642	21	11	and	and	CCONJ
dpc-4642	21	12	elevated	elevated	ADJ
dpc-4642	21	13	rates	rate	NOUN
dpc-4642	21	14	of	of	ADP
dpc-4642	21	15	recurrence	recurrence	NOUN
dpc-4642	21	16	,	,	PUNCT
dpc-4642	21	17	metastasis	metastasis	NOUN
dpc-4642	21	18	,	,	PUNCT
dpc-4642	21	19	and	and	CCONJ
dpc-4642	21	20	mortality	mortality	NOUN
dpc-4642	22	1	[	[	X
dpc-4642	22	2	1	1	NUM
dpc-4642	22	3	]	]	PUNCT
dpc-4642	22	4	.	.	PUNCT
dpc-4642	23	1	due	due	ADP
dpc-4642	23	2	to	to	ADP
dpc-4642	23	3	the	the	DET
dpc-4642	23	4	additive	additive	ADJ
dpc-4642	23	5	therapeutic	therapeutic	ADJ
dpc-4642	23	6	effectiveness	effectiveness	NOUN
dpc-4642	23	7	of	of	ADP
dpc-4642	23	8	interferon	interferon	NOUN
dpc-4642	23	9	(	(	PUNCT
dpc-4642	23	10	ifn	ifn	PROPN
dpc-4642	23	11	)	)	PUNCT
dpc-4642	23	12	and	and	CCONJ
dpc-4642	23	13	pd-1	pd-1	ADV
dpc-4642	23	14	/	/	SYM
dpc-4642	23	15	pd	pd	ADJ
dpc-4642	23	16	-	-	PUNCT
dpc-4642	23	17	l1	l1	PROPN
dpc-4642	23	18	inhibition	inhibition	NOUN
dpc-4642	23	19	across	across	ADP
dpc-4642	23	20	various	various	ADJ
dpc-4642	23	21	cancer	cancer	NOUN
dpc-4642	23	22	types	type	NOUN
dpc-4642	23	23	and	and	CCONJ
dpc-4642	23	24	in	in	ADP
dpc-4642	23	25	particular	particular	ADJ
dpc-4642	23	26	in	in	ADP
dpc-4642	23	27	melanoma	melanoma	NOUN
dpc-4642	23	28	,	,	PUNCT
dpc-4642	23	29	anti	anti	ADJ
dpc-4642	23	30	-	-	ADJ
dpc-4642	23	31	pd-1	pd-1	ADJ
dpc-4642	23	32	treatment	treatment	NOUN
dpc-4642	23	33	such	such	ADJ
dpc-4642	23	34	as	as	ADP
dpc-4642	23	35	cemiplimab	cemiplimab	NOUN
dpc-4642	23	36	was	be	AUX
dpc-4642	23	37	considered	consider	VERB
dpc-4642	23	38	as	as	ADP
dpc-4642	23	39	an	an	DET
dpc-4642	23	40	additional	additional	ADJ
dpc-4642	23	41	treatment	treatment	NOUN
dpc-4642	23	42	for	for	ADP
dpc-4642	23	43	this	this	DET
dpc-4642	23	44	locally	locally	ADV
dpc-4642	23	45	advanced	advanced	ADJ
dpc-4642	23	46	and	and	CCONJ
dpc-4642	23	47	recurrent	recurrent	ADJ
dpc-4642	23	48	scc	scc	NOUN
dpc-4642	24	1	[	[	X
dpc-4642	24	2	2	2	NUM
dpc-4642	24	3	]	]	PUNCT
dpc-4642	24	4	.	.	PUNCT
dpc-4642	25	1	our	our	PRON
dpc-4642	25	2	case	case	NOUN
dpc-4642	25	3	supports	support	VERB
dpc-4642	25	4	the	the	DET
dpc-4642	25	5	co	co	NOUN
dpc-4642	25	6	-	-	NOUN
dpc-4642	25	7	administration	administration	NOUN
dpc-4642	25	8	of	of	ADP
dpc-4642	25	9	an	an	DET
dpc-4642	25	10	anti	anti	ADJ
dpc-4642	25	11	-	-	ADJ
dpc-4642	25	12	pd-1	pd-1	ADJ
dpc-4642	25	13	antagonist	antagonist	NOUN
dpc-4642	25	14	with	with	ADP
dpc-4642	25	15	ifn	ifn	PROPN
dpc-4642	25	16	to	to	PART
dpc-4642	25	17	control	control	VERB
dpc-4642	25	18	both	both	CCONJ
dpc-4642	25	19	scc	scc	NOUN
dpc-4642	25	20	and	and	CCONJ
dpc-4642	25	21	pv	pv	VERB
dpc-4642	25	22	in	in	ADP
dpc-4642	25	23	a	a	DET
dpc-4642	25	24	patient	patient	NOUN
dpc-4642	25	25	with	with	ADP
dpc-4642	25	26	scc	scc	ADJ
dpc-4642	25	27	aggravation	aggravation	NOUN
dpc-4642	25	28	following	follow	VERB
dpc-4642	25	29	ruxolitinib	ruxolitinib	PROPN
dpc-4642	25	30	exposure	exposure	NOUN
dpc-4642	25	31	.	.	PUNCT
dpc-4642	26	1	references	reference	NOUN
dpc-4642	26	2	1	1	NUM
dpc-4642	26	3	.	.	PUNCT
dpc-4642	27	1	lin	lin	PROPN
dpc-4642	27	2	jq	jq	PROPN
dpc-4642	27	3	,	,	PUNCT
dpc-4642	27	4	li	li	PROPN
dpc-4642	27	5	sq	sq	PROPN
dpc-4642	27	6	,	,	PUNCT
dpc-4642	27	7	li	li	PROPN
dpc-4642	27	8	s	s	PROPN
dpc-4642	27	9	,	,	PUNCT
dpc-4642	27	10	et	et	PROPN
dpc-4642	27	11	al	al	PROPN
dpc-4642	27	12	.	.	PUNCT
dpc-4642	28	1	a	a	DET
dpc-4642	28	2	10	10	NUM
dpc-4642	28	3	-	-	PUNCT
dpc-4642	28	4	year	year	NOUN
dpc-4642	28	5	retrospective	retrospective	ADJ
dpc-4642	28	6	cohort	cohort	NOUN
dpc-4642	28	7	study	study	NOUN
dpc-4642	28	8	of	of	ADP
dpc-4642	28	9	ruxolitinib	ruxolitinib	NOUN
dpc-4642	28	10	and	and	CCONJ
dpc-4642	28	11	association	association	NOUN
dpc-4642	28	12	with	with	ADP
dpc-4642	28	13	nonmelanoma	nonmelanoma	PROPN
dpc-4642	28	14	skin	skin	NOUN
dpc-4642	28	15	cancer	cancer	NOUN
dpc-4642	28	16	in	in	ADP
dpc-4642	28	17	patients	patient	NOUN
dpc-4642	28	18	with	with	ADP
dpc-4642	28	19	polycythemia	polycythemia	NOUN
dpc-4642	28	20	vera	vera	NOUN
dpc-4642	28	21	and	and	CCONJ
dpc-4642	28	22	myelofibrosis	myelofibrosis	NOUN
dpc-4642	28	23	.	.	PUNCT
dpc-4642	29	1	j	j	PROPN
dpc-4642	29	2	am	be	AUX
dpc-4642	29	3	acad	acad	ADJ
dpc-4642	29	4	dermatol	dermatol	NOUN
dpc-4642	29	5	.	.	PUNCT
dpc-4642	30	1	202;86(2):339	202;86(2):339	PROPN
dpc-4642	30	2	-	-	PUNCT
dpc-4642	30	3	344	344	NUM
dpc-4642	30	4	.	.	PUNCT
dpc-4642	30	5	doi	doi	NOUN
dpc-4642	30	6	:	:	PUNCT
dpc-4642	30	7	10.1016	10.1016	NUM
dpc-4642	30	8	/	/	SYM
dpc-4642	30	9	j.jaad.2021	j.jaad.2021	PROPN
dpc-4642	30	10	.10.004	.10.004	PUNCT
dpc-4642	30	11	.	.	PUNCT
dpc-4642	31	1	pmid	pmid	NOUN
dpc-4642	31	2	:	:	PUNCT
dpc-4642	31	3	34648874	34648874	NUM
dpc-4642	31	4	.	.	PUNCT
dpc-4642	32	1	2	2	X
dpc-4642	32	2	.	.	X
dpc-4642	32	3	razaghi	razaghi	PROPN
dpc-4642	32	4	a	a	DET
dpc-4642	32	5	,	,	PUNCT
dpc-4642	32	6	durand	durand	NOUN
dpc-4642	32	7	-	-	PUNCT
dpc-4642	32	8	dubief	dubief	PROPN
dpc-4642	32	9	m	m	PROPN
dpc-4642	32	10	,	,	PUNCT
dpc-4642	32	11	brusselaers	brusselaer	NOUN
dpc-4642	32	12	n	n	CCONJ
dpc-4642	32	13	,	,	PUNCT
dpc-4642	32	14	björnstedt	björnstedt	ADJ
dpc-4642	32	15	m.	m.	NOUN
dpc-4642	32	16	combining	combine	VERB
dpc-4642	32	17	pd-1	pd-1	ADP
dpc-4642	32	18	/	/	SYM
dpc-4642	32	19	pd	pd	ADJ
dpc-4642	32	20	-	-	PUNCT
dpc-4642	32	21	l1	l1	PROPN
dpc-4642	32	22	blockade	blockade	NOUN
dpc-4642	32	23	with	with	ADP
dpc-4642	32	24	type	type	NOUN
dpc-4642	32	25	i	i	PRON
dpc-4642	32	26	interferon	interferon	ADJ
dpc-4642	32	27	in	in	ADP
dpc-4642	32	28	cancer	cancer	NOUN
dpc-4642	32	29	therapy	therapy	NOUN
dpc-4642	32	30	.	.	PUNCT
dpc-4642	33	1	front	front	ADJ
dpc-4642	33	2	immunol	immunol	NOUN
dpc-4642	33	3	.	.	PUNCT
dpc-4642	34	1	2023;14:1249330	2023;14:1249330	NUM
dpc-4642	34	2	.	.	X
dpc-4642	34	3	doi	doi	NOUN
dpc-4642	34	4	:	:	PUNCT
dpc-4642	34	5	10.3389	10.3389	NUM
dpc-4642	34	6	/	/	SYM
dpc-4642	34	7	fimmu	fimmu	ADJ
dpc-4642	34	8	.2023.1249330	.2023.1249330	PROPN
dpc-4642	34	9	.	.	PUNCT
dpc-4642	35	1	pmid	pmid	NOUN
dpc-4642	35	2	:	:	PUNCT
dpc-4642	35	3	37691915	37691915	NUM
dpc-4642	35	4	.	.	PUNCT
dpc-4642	36	1	pmcid	pmcid	NOUN
dpc-4642	36	2	:	:	PUNCT
dpc-4642	36	3	pmc10484344	pmc10484344	NOUN
dpc-4642	36	4	.	.	PUNCT
dpc-4642	37	1	figure	figure	NOUN
dpc-4642	37	2	1	1	NUM
dpc-4642	37	3	.	.	PUNCT
dpc-4642	38	1	(	(	PUNCT
dpc-4642	38	2	a	a	DET
dpc-4642	38	3	,	,	PUNCT
dpc-4642	38	4	b	b	NOUN
dpc-4642	38	5	)	)	PUNCT
dpc-4642	38	6	.	.	PUNCT
dpc-4642	39	1	patient	patient	ADJ
dpc-4642	39	2	undergoing	undergo	VERB
dpc-4642	39	3	ruxolitinib	ruxolitinib	PROPN
dpc-4642	39	4	treatment	treatment	NOUN
dpc-4642	39	5	exhibited	exhibit	VERB
dpc-4642	39	6	scc	scc	ADJ
dpc-4642	39	7	progression	progression	NOUN
dpc-4642	39	8	,	,	PUNCT
dpc-4642	39	9	manifesting	manifest	VERB
dpc-4642	39	10	as	as	ADP
dpc-4642	39	11	a	a	DET
dpc-4642	39	12	significant	significant	ADJ
dpc-4642	39	13	,	,	PUNCT
dpc-4642	39	14	ulcerated	ulcerated	ADJ
dpc-4642	39	15	lesion	lesion	NOUN
dpc-4642	39	16	on	on	ADP
dpc-4642	39	17	the	the	DET
dpc-4642	39	18	nose	nose	NOUN
dpc-4642	39	19	tip	tip	NOUN
dpc-4642	39	20	,	,	PUNCT
dpc-4642	39	21	draining	drain	VERB
dpc-4642	39	22	pus	pus	NOUN
dpc-4642	39	23	.	.	PUNCT
dpc-4642	40	1	(	(	PUNCT
dpc-4642	40	2	c	c	X
dpc-4642	40	3	,	,	PUNCT
dpc-4642	40	4	d	d	NOUN
dpc-4642	40	5	)	)	PUNCT
dpc-4642	40	6	.	.	PUNCT
dpc-4642	41	1	following	follow	VERB
dpc-4642	41	2	treatment	treatment	NOUN
dpc-4642	41	3	,	,	PUNCT
dpc-4642	41	4	the	the	DET
dpc-4642	41	5	lesion	lesion	NOUN
dpc-4642	41	6	notably	notably	ADV
dpc-4642	41	7	improved	improve	VERB
dpc-4642	41	8	,	,	PUNCT
dpc-4642	41	9	with	with	ADP
dpc-4642	41	10	the	the	DET
dpc-4642	41	11	cancerous	cancerous	ADJ
dpc-4642	41	12	mass	mass	NOUN
dpc-4642	41	13	diminishing	diminishing	NOUN
dpc-4642	41	14	and	and	CCONJ
dpc-4642	41	15	the	the	DET
dpc-4642	41	16	lesion	lesion	NOUN
dpc-4642	41	17	re	re	NOUN
dpc-4642	41	18	-	-	NOUN
dpc-4642	41	19	epithelializing	epithelializing	ADJ
dpc-4642	41	20	.	.	PUNCT
dpc-4642	42	1	this	this	DET
dpc-4642	42	2	transformation	transformation	NOUN
dpc-4642	42	3	occurred	occur	VERB
dpc-4642	42	4	after	after	ADP
dpc-4642	42	5	the	the	DET
dpc-4642	42	6	fourth	fourth	ADJ
dpc-4642	42	7	dose	dose	NOUN
dpc-4642	42	8	of	of	ADP
dpc-4642	42	9	cemiplimab	cemiplimab	NOUN
dpc-4642	42	10	(	(	PUNCT
dpc-4642	42	11	350	350	NUM
dpc-4642	42	12	mg	mg	PROPN
dpc-4642	42	13	cemiplimab	cemiplimab	NOUN
dpc-4642	42	14	,	,	PUNCT
dpc-4642	42	15	every	every	DET
dpc-4642	42	16	3	3	NUM
dpc-4642	42	17	weeks	week	NOUN
dpc-4642	42	18	)	)	PUNCT
dpc-4642	42	19	,	,	PUNCT
dpc-4642	42	20	alongside	alongside	ADP
dpc-4642	42	21	ongoing	ongoing	ADJ
dpc-4642	42	22	ropeginterferon	ropeginterferon	PROPN
dpc-4642	42	23	α-2b	α-2b	PROPN
dpc-4642	42	24	therapy	therapy	NOUN
dpc-4642	42	25	.	.	PUNCT